EIF4E and Miyoshi myopathy: In order to test the validity of our Timlip for eIF4E and eIF4GI we assayed the expression of the designated and established targets in MM cell lines treated with an eIF4E inhibitor (RBV) (RPMI-8226, CAG) and an inhibitor of the factors' association (4EGI) (RPMI 8226, U266, ARK, ARP1) as described in our previous publication [12–14].